-
1.发明授权Monoclonal antibodies binding to avian influenza virus subtype H5 haemagglutinin and uses thereof 有权结合禽流感病毒亚型H5血细胞凝集素的单克隆抗体及其用途公开(公告)号：US08603467B2
公开(公告)日：2013-12-10
申请号：US12664696
申请日：2008-06-16
申请人： Yixin Chen , Wenxin Luo , Jun Zhang , Ningshao Xia , Yi Guan , Honglin Chen
发明人： Yixin Chen , Wenxin Luo , Jun Zhang , Ningshao Xia , Yi Guan , Honglin Chen
IPC分类号： A61K39/42
CPC分类号： C07K16/1018 , A61K2039/505 , C07K2317/24 , C07K2317/622 , C07K2317/76 , C12N2760/16111 , G01N33/56983 , G01N2333/11
摘要： The present invention provides monoclonal antibodies that bind specifically to H5 subtype avian influenza virus hemagglutinin (HA) proteins, and can block the binding activity of at least 50% of the known monoclonal antibodies to the H5 subtype avian influenza virus hemagglutinin (HA) protein. The monoclonal antibodies can be used for the detection, diagnosis, prevention, and treatment of avian influenza viruses, especially the H5 subtype of avian influenza viruses. The present invention also provides the related hybridoma cell lines, isolated nucleic acid molecules and short peptides, as well as medical composition and medical diagnostic equipment and kit containing the monoclonal antibody.
摘要翻译： 本发明提供了与H5亚型禽流感病毒血凝素（HA）蛋白特异性结合的单克隆抗体，并且可以阻断至少50％的已知单克隆抗体与H5亚型禽流感病毒血凝素（HA）蛋白的结合活性。 单克隆抗体可用于检测，诊断，预防和治疗禽流感病毒，特别是禽流感病毒的H5亚型。 本发明还提供了相关的杂交瘤细胞系，分离的核酸分子和短肽，以及包含单克隆抗体的医药组合物和医学诊断设备和试剂盒。
-
2.发明申请MONOCLONAL ANTIBODIES BINDING TO AVIAN INFLUENZA VIRUS SUBTYPE H5 HAEMAGGLUTININ AND USES THEREOF 有权单克隆抗体与AVIAN流感病毒亚型H5 HAEMAGGLUTININ结合及其用途公开(公告)号：US20110311522A1
公开(公告)日：2011-12-22
申请号：US12664696
申请日：2008-06-16
申请人： Yixin Chen , Wenxin Luo , Jun Zhang , Ningshao Xia , Yi Guan , Honglin Chen
发明人： Yixin Chen , Wenxin Luo , Jun Zhang , Ningshao Xia , Yi Guan , Honglin Chen
CPC分类号： C07K16/1018 , A61K2039/505 , C07K2317/24 , C07K2317/622 , C07K2317/76 , C12N2760/16111 , G01N33/56983 , G01N2333/11
摘要： The present invention provides monoclonal antibodies that bind specifically to H5 subtype avian influenza virus hemagglutinin (HA) proteins, and can block the binding activity of at least 50% of the known monoclonal antibodies to the H5 subtype avian influenza virus hemagglutinin (HA) protein. The monoclonal antibodies can be used for the detection, diagnosis, prevention, and treatment of avian influenza viruses, especially the H5 subtype of avian influenza viruses. The present invention also provides the related hybridoma cell lines, isolated nucleic acid molecules and short peptides, as well as medical composition and medical diagnostic equipment and kit containing the monoclonal antibody.
摘要翻译： 本发明提供了与H5亚型禽流感病毒血凝素（HA）蛋白特异性结合的单克隆抗体，并且可以阻断至少50％的已知单克隆抗体与H5亚型禽流感病毒血凝素（HA）蛋白的结合活性。 单克隆抗体可用于检测，诊断，预防和治疗禽流感病毒，特别是禽流感病毒的H5亚型。 本发明还提供了相关的杂交瘤细胞系，分离的核酸分子和短肽，以及包含单克隆抗体的医药组合物和医学诊断设备和试剂盒。
-
3.发明申请MONOCLONAL ANTIBODIES BINDING TO AVIAN INFLUENZA VIRUS SUBTYPE H5 HAEMAGGLUTININ AND USE THEREOF 审中-公开单克隆抗体与AVIAN流感病毒亚型H5 HAEMAGGLUTININ结合及其用途公开(公告)号：US20090068637A1
公开(公告)日：2009-03-12
申请号：US12162343
申请日：2007-01-26
申请人： Ningshao Xia , Yixin Chen , Shengxiang Ge , Wenxin Luo , Jun Zhang
发明人： Ningshao Xia , Yixin Chen , Shengxiang Ge , Wenxin Luo , Jun Zhang
CPC分类号： C07K16/1018 , A61K47/646 , A61K47/6901 , B82Y15/00 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/76
摘要： The present application provides monoclonal antibodies that specifically bind to the hemagglutinin of avian influenza virus subtype H5, as well as monoclonal antibodies capable of blocking at least 50% of the hemagglutinin binding activity of these monoclonal antibodies. Such antibodies are useful, for example, in the detection, diagnosis, prevention, and treatment of avian influenza virus. Also provided herein are hybridoma cell lines, isolated nucleic acid molecules, and short peptides related to the monoclonal antibodies provided herein, and pharmaceutical compositions and kits containing the monoclonal antibodies provided herein.
摘要翻译： 本申请提供了特异性结合禽流感病毒亚型H5的血凝素的单克隆抗体，以及能够阻断这些单克隆抗体的至少50％血凝素结合活性的单克隆抗体。 这样的抗体可用于例如禽流感病毒的检测，诊断，预防和治疗。 本文还提供杂交瘤细胞系，分离的核酸分子和与本文提供的单克隆抗体相关的短肽，以及含有本文提供的单克隆抗体的药物组合物和试剂盒。
-
公开(公告)号：US09428555B2
公开(公告)日：2016-08-30
申请号：US12598186
申请日：2008-04-29
申请人： Ying Gu , Shaowei Li , Minxi Wei , Yangling Xian , Wenxin Luo , Ningshao Xia
发明人： Ying Gu , Shaowei Li , Minxi Wei , Yangling Xian , Wenxin Luo , Ningshao Xia
IPC分类号： C07K14/005 , A61K39/12 , C12N7/00 , A61K39/00
CPC分类号： C07K14/005 , A61K39/12 , A61K2039/5258 , A61K2039/55505 , A61K2039/55566 , A61K2039/70 , C12N7/00 , C12N2710/20022 , C12N2710/20034
摘要： The invention relates to a truncated L1 protein of the Human Papillomavirus Type 16, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of cervical cancer.
摘要翻译： 本发明涉及16型人乳头瘤病毒的截短L1蛋白，由蛋白质组成的病毒样颗粒，包含所述病毒样颗粒的疫苗，以及该疫苗在预防子宫颈癌中的用途。
-
5.发明申请FUSION PROTEIN COMPRISING DIPTHERIA TOXIN NON-TOXIC MUTANT CRM197 OR FRAGMENT THEREOF 有权含有DIPILIA TOXIN非毒性突变体CRM197或其片段的融合蛋白公开(公告)号：US20140134199A1
公开(公告)日：2014-05-15
申请号：US14123305
申请日：2012-06-01
申请人： Shaowei Li , Cuiling Song , Chunyan Yang , Ying Gu , Wenxin Luo , Ningshao Xia
发明人： Shaowei Li , Cuiling Song , Chunyan Yang , Ying Gu , Wenxin Luo , Ningshao Xia
IPC分类号： C07K14/005 , C12N9/10
CPC分类号： A61K39/39 , A61K38/00 , A61K39/05 , A61K39/12 , A61K39/29 , A61K2039/55505 , A61K2039/55516 , A61K2039/55544 , A61K2039/6037 , C07K14/005 , C07K14/34 , C07K2319/03 , C07K2319/55 , C07K2319/74 , C12N7/00 , C12N9/1048 , C12N15/62 , C12N2760/16122 , C12N2760/16134 , C12N2770/28122 , C12N2770/28134
摘要： Provided in the present invention are a diphtheria toxin non-toxic mutant CRM197 or a fragment thereof as an adjuvant in a fusion protein and the use thereof to enhance the immunogenicity of a target protein fused therewith, for example, an HEV capsid protein, or an influenza virus M2 protein or an immunogenic fragment thereof. Also provided is a method for enhancing the immunogenicity of a target protein, comprising the fusion expression of the CRM197 or the fragment thereof with the target protein to form a fusion protein. Further provided is a fusion protein comprising the CRM197 or the fragment thereof and a target protein, the CRM197 or the fragment thereof enhancing the immunogenicity of the target protein. The present invention also provides an isolated nucleic acid encoding the fusion protein, a construct and a vector comprising said nucleic acid, and a host cell comprising the nucleic acid.
摘要翻译： 在本发明中提供了作为融合蛋白中的佐剂的白喉毒素无毒突变体CRM197或其片段，以及用于增强与其融合的靶蛋白的免疫原性的用途，例如HEV衣壳蛋白或 流感病毒M2蛋白或其免疫原性片段。 还提供了增强靶蛋白的免疫原性的方法，其包括将CRM197或其片段与靶蛋白的融合表达形成融合蛋白。 还提供了包含CRM197或其片段和靶蛋白的融合蛋白，CRM197或其片段增强靶蛋白的免疫原性。 本发明还提供编码融合蛋白的分离的核酸，包含所述核酸的构建体和载体，以及包含所述核酸的宿主细胞。
-
6.发明授权Fusion protein comprising diphtheria toxin non-toxic mutant CRM197 or fragment thereof 有权包含白喉毒素无毒突变体CRM197或其片段的融合蛋白公开(公告)号：US09512185B2
公开(公告)日：2016-12-06
申请号：US14123305
申请日：2012-06-01
申请人： Shaowei Li , Cuiling Song , Chunyan Yang , Ying Gu , Wenxin Luo , Ningshao Xia
发明人： Shaowei Li , Cuiling Song , Chunyan Yang , Ying Gu , Wenxin Luo , Ningshao Xia
CPC分类号： A61K39/39 , A61K38/00 , A61K39/05 , A61K39/12 , A61K39/29 , A61K2039/55505 , A61K2039/55516 , A61K2039/55544 , A61K2039/6037 , C07K14/005 , C07K14/34 , C07K2319/03 , C07K2319/55 , C07K2319/74 , C12N7/00 , C12N9/1048 , C12N15/62 , C12N2760/16122 , C12N2760/16134 , C12N2770/28122 , C12N2770/28134
摘要： Provided in the present invention are a diphtheria toxin non-toxic mutant CRM197 or a fragment thereof as an adjuvant in a fusion protein and the use thereof to enhance the immunogenicity of a target protein fused therewith, for example, an HEV capsid protein, or an influenza virus M2 protein or an immunogenic fragment thereof. Also provided is a method for enhancing the immunogenicity of a target protein, comprising the fusion expression of the CRM197 or the fragment thereof with the target protein to form a fusion protein. Further provided is a fusion protein comprising the CRM197 or the fragment thereof and a target protein, the CRM197 or the fragment thereof enhancing the immunogenicity of the target protein. The present invention also provides an isolated nucleic acid encoding the fusion protein, a construct and a vector comprising said nucleic acid, and a host cell comprising the nucleic acid.
摘要翻译： 本发明中提供了作为融合蛋白中的佐剂的白喉毒素无毒突变体CRM197或其片段及其与其融合的靶蛋白的免疫原性的用途，例如HEV衣壳蛋白或 流感病毒M2蛋白或其免疫原性片段。 还提供了增强靶蛋白的免疫原性的方法，其包括将CRM197或其片段与靶蛋白的融合表达形成融合蛋白。 还提供了包含CRM197或其片段和靶蛋白的融合蛋白，CRM197或其片段增强靶蛋白的免疫原性。 本发明还提供编码融合蛋白的分离的核酸，包含所述核酸的构建体和载体，以及包含所述核酸的宿主细胞。
-
公开(公告)号：US20100255031A1
公开(公告)日：2010-10-07
申请号：US12598186
申请日：2008-04-29
申请人： Ying Gu , Shaowei Li , Minxi Wei , Yangling Xian , Wenxin Luo , Ningshao Xia
发明人： Ying Gu , Shaowei Li , Minxi Wei , Yangling Xian , Wenxin Luo , Ningshao Xia
IPC分类号： A61K39/12 , C07K14/025 , C07H21/04 , C12N15/74 , C12N1/21 , A61K38/16 , C12P21/00 , A61P31/20 , A61P37/04
CPC分类号： C07K14/005 , A61K39/12 , A61K2039/5258 , A61K2039/55505 , A61K2039/55566 , A61K2039/70 , C12N7/00 , C12N2710/20022 , C12N2710/20034
摘要： The invention relates to a truncated L1 protein of the Human Papillomavirus Type 16, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of cervical cancer.
摘要翻译： 本发明涉及16型人乳头瘤病毒的截短L1蛋白，由蛋白质组成的病毒样颗粒，包含所述病毒样颗粒的疫苗，以及该疫苗在预防子宫颈癌中的用途。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.028 秒)
